NCT02935530

Thromboprophylaxis After Surgery for Gynecologic Malignancy in China

Effectiveness and Safety of Thromboprophylaxis After Surgery for Gynecologic Malignancy in China

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 315 (actual)
• Sponsor: Huazhong University of Science and Technology · Academic / Other
• Sex: Female
• Age: 16 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Venous thromboembolism (VTE) is an important cause of post-operative morbidity and mortality in women undergoing surgery for gynecologic malignancies. Although the benefit of thromboprophylaxis in reduction of post-operative VTE events after surgery for gynecologic cancers has been well documented around the world, the evidence for Chinese women is rare. The investigators designed this prospective and randomized study to assess the benefit of pharmacologic prophylaxis for patients received surgical treatment for gynecologic malignancies in China.

Conditions

• Gynecologic Neoplasms
• Venous Thromboembolism
• Low Molecular Weight Heparin
• Argatroban

Interventions

Type	Name	Description
DRUG	s-LMWH	2125KU, subcutaneous injection of 5-10 days
DRUG	LMWH	4250KU, subcutaneous injection of 5-10 days
DRUG	Argatroban	20mg, injection for 5-10 days

Timeline

• Start date: 2016-01-01
• Primary completion: 2017-08-01
• Completion: 2017-10-01
• First posted: 2016-10-17
• Last updated: 2019-05-14

Locations

1 site across 1 country: China